A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Phase 2 Study of the Safety and Efficacy of ABT-126 in the Treatment of Cognitive Deficits in Schizophrenia (CDS) in Smokers.

Trial Profile

A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Phase 2 Study of the Safety and Efficacy of ABT-126 in the Treatment of Cognitive Deficits in Schizophrenia (CDS) in Smokers.

Completed
Phase of Trial: Phase II

Latest Information Update: 27 Mar 2015

At a glance

  • Drugs Nelonicline (Primary)
  • Indications Cognition disorders
  • Focus Therapeutic Use
  • Sponsors AbbVie
  • Most Recent Events

    • 27 Mar 2014 Trial status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 19 Nov 2013 Planned End Date changed from 1 Feb 2014 to 1 Mar 2014 as reported by ClinicalTrials.gov.
    • 19 Nov 2013 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top